Open Access. Powered by Scholars. Published by Universities.®

Chemicals and Drugs Commons

Open Access. Powered by Scholars. Published by Universities.®

Honors Scholars Collaborative Projects

Series

Clinical trials

Articles 1 - 1 of 1

Full-Text Articles in Chemicals and Drugs

Selinexor Hyperactivates Akt And Induces Its Nuclear Accumulation, Erin Lawrence Apr 2020

Selinexor Hyperactivates Akt And Induces Its Nuclear Accumulation, Erin Lawrence

Honors Scholars Collaborative Projects

Selinexor is currently being used in several clinical trials for cancer and has shown anti-cancer effects in combination with other chemotherapies. Clinical trials evaluating the use of selinexor in the treatment of triple negative breast cancer are limited, but in vitro studies show promising results in its ability to kill triple negative breast cancer cells. The mechanism by which this occurs, however, is not understood. The goal of this research was to determine the mechanism by which selinexor kills BT- 549 triple negative breast cancer cells.